Alchemab Therapeutics Ltd

Founded in 2019, Alchemab is a clinical-stage biotechnology company uncovering autoprotective antibodies from disease-resilient individuals to discover and develop novel therapeutics. The company’s Resiliome™ platform integrates the world’s largest antibody database derived from disease-resilient individuals with advanced AI and lab validation to identify and characterise the antibodies that protect them. By pioneering this approach, Alchemab has generated a broad pipeline of first- and best-in-class assets for hard-to-treat diseases. Alchemab’s current investors include SV Health Investors (including SV’s Dementia Discovery Fund), RA Capital Management, DCVC Bio, Eli Lilly, Lightstone Ventures, Ono Venture Investment, and Camford Partners.